Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Alnylam Pharmaceuticals (NQ: ALNY ) 273.91 +7.32 (+2.75%) Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Alnylam Pharmaceuticals < Previous 1 2 3 4 5 6 7 8 9 ... 15 16 Next > Expert Ratings for Alnylam Pharmaceuticals October 16, 2023 Via Benzinga 10 Health Care Stocks Whale Activity In Today's Session October 11, 2023 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2023 October 11, 2023 Via Benzinga Analyst Expectations for Alnylam Pharmaceuticals's Future September 29, 2023 Via Benzinga What 16 Analyst Ratings Have To Say About Alnylam Pharmaceuticals September 12, 2023 Via Benzinga CSX To Rally Around 27%? Here Are 10 Other Analyst Forecasts For Wednesday October 11, 2023 Morgan Stanley cut Netflix, Inc. (NASDAQ: NFLX) price target from $450 to $430. Morgan Stanley analyst Benjamin Swinburne maintained an Equal-Weight rating. Netflix shares rose 0.8% to $375.51 in... Via Benzinga Why Is Genetic Disease-Focused Alnylam Pharmaceuticals Stock Trading Lower Today? October 09, 2023 The FDA has issued a Complete Response Letter (CRL) to Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) supplemental New Drug Application (sNDA) for patisiran for cardiomyopathy of transthyretin- Via Benzinga Exposures Product Safety Alnylam Stock Crumbles After The FDA Unexpectedly Rejects Its Heart Drug October 09, 2023 Shares skidded to their lowest point since September on the FDA's rejection. Via Investor's Business Daily Exposures Product Safety Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis October 09, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire 2 Growth Stocks That Could Rocket Higher Before the End of 2023 October 08, 2023 Potential approvals of new medicines expected soon could push these stocks through the roof. Via The Motley Fool Alnylam to Present Additional Data for Patisiran in Patients With the Cardiomyopathy of ATTR Amyloidosis, Including 24-Month Results From the APOLLO-B Phase 3 Study, at the Heart Failure Society of America Annual Scientific Meeting 2023 October 06, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire 10 Health Care Stocks Whale Activity In Today's Session October 05, 2023 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023 September 29, 2023 Via Benzinga Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges September 27, 2023 Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY Via Benzinga Argenx's 28% Surge & Promising Product Propel Investor Confidence September 25, 2023 Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target. Via MarketBeat Potential Label Restrictions Loom For Alnylam's Patisiran Despite Approval Prospects September 14, 2023 On Wednesday, an FDA advisory committee voted 9-3 in favor of Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) patisiran. Via Benzinga Exposures Product Safety Alnylam Pharma Tumbles After FDA Advisors Dash Its Hopes Of Rivaling Pfizer September 14, 2023 Its heart disease drug could gain approval, but FDA advisors don't expect it to take on Pfizer's leading drug. Via Investor's Business Daily Exposures Product Safety Despite FDA Doubts, Adcomm Backs Alnylam's Gene Silencing Therapy For Expanded Use Into Rare Heart Disease September 14, 2023 On Wednesday, an FDA advisory committee voted 9-3 in favor of Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) patisiran. Via Benzinga Exposures Product Safety Nasdaq, S&P 500 Futures In Green As Traders Look Past Inflation Data; Analyst Singles Out Key Catalyst That Can Keep Year's Rally Going September 14, 2023 US stocks could open Thursday's session higher, apparently in relief rally following the August inflation data. Via Benzinga Topics Economy Stocks Exposures Interest Rates US Equities Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis September 13, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Buy List Alert: 3 Pharma Stocks with Positive Trial Updates September 13, 2023 These three pharma stocks could be driven higher amidst future revenue prospects as they report to investors positive clinical developments. Via InvestorPlace Alnylam Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis September 13, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Here's How Much $1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth Today September 11, 2023 Via Benzinga 10 Health Care Stocks With Whale Alerts In Today's Session September 08, 2023 Via Benzinga Cramer Says 'Please Stay Away' From This EV Maker, It 'Should Not Be Public' September 08, 2023 On CNBC’s "Mad Money Lightning Round," Jim Cramer said Norfolk Southern Corporation (NYSE: NSC) is the "cheapest I’ve seen in a very long time, Via Benzinga Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study, Offering Hope September 07, 2023 Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) for hypertension, Via Benzinga Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular Risk September 07, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire 3 Stocks to Buy For the COVID Resurgence September 06, 2023 The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting Via MarketBeat Exposures COVID-19 Product Safety Here's How Much $100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth Today September 05, 2023 Via Benzinga Alnylam to Appeal Claim Construction Ruling on Two Patents Asserted Against Moderna August 25, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire < Previous 1 2 3 4 5 6 7 8 9 ... 15 16 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
